Drug Repurposing Market Report 2025

The drug repurposing market size has grown strongly in recent years. It will grow from $34.12 billion in 2024 to $37.38 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth during the historic period can be attributed to the escalating costs of developing new drugs, a growing number of drug failures in clinical trials, increased demand for quicker drug approvals, greater availability of off-patent medications, and rising levels of government and academic research funding.

The drug repurposing market size is expected to see strong growth in the next few years. It will grow to $53.42 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be credited to the rising demand for cost-effective therapies, increased investments by pharmaceutical companies, growing partnerships among biotech firms, and the broadening scope of applications in oncology and neurology. Key trends anticipated during the forecast period include progress in computational drug discovery tools, enhanced utilization of artificial intelligence and machine learning in drug repurposing, innovations in predictive modeling for assessing drug efficacy, the integration of big data analytics into drug screening processes, and advancements in the identification of biomarkers.

The increasing prevalence of neurodegenerative diseases is expected to drive the growth of the drug repurposing market in the future. Neurodegenerative diseases are a group of disorders marked by the progressive loss of neuron structure or function, including neuronal death. The rise in conditions such as Alzheimer’s dementia is largely due to increased life expectancy, as aging remains the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing aids in treating neurodegenerative diseases by identifying existing drugs with established safety profiles that can be redirected to target relevant disease pathways, thereby speeding up the development of effective therapies. For example, in March 2023, the Alzheimer's Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating an increase to 13.8 million by 2060. Consequently, the rising prevalence of neurodegenerative diseases is fueling the expansion of the drug repurposing market.

Key companies in the drug repurposing market are investing in cutting-edge technologies such as artificial intelligence (AI)-powered drug-protein interaction modeling to hasten the discovery of new therapeutic applications for existing drugs. AI-powered drug-protein interaction modeling uses artificial intelligence and machine learning to predict how drugs interact with proteins across the human proteome, leveraging extensive datasets to improve accuracy and confidence. For instance, in July 2025, Cosmos Health Inc., a US-based healthcare company, launched Cloudscreen 2.0, an advanced AI platform designed for drug repurposing. This next-generation system processes datasets over 100 times larger than before, enabling comprehensive analysis of drug-protein interactions. By integrating mutagenesis data and tools to analyze disordered proteins, the platform targets diseases including cancer, obesity, and diabetes. Furthermore, GPU-based cloud computing supports scalable processing, making the platform a significant innovation for accelerating research and development pipelines across multiple therapeutic areas.

In July 2025, Predictive Oncology Inc., a US-based company specializing in AI-driven drug discovery and repurposing, partnered with YA II PN, Ltd., securing a $10 million share purchase agreement. Through this collaboration, Predictive Oncology aims to enhance its AI-driven platform to speed up the identification of new therapeutic uses for existing drugs and optimize oncology drug discovery processes. YA II PN, Ltd. is a US-based investment fund managed by Yorkville Advisors Global, LP, which provides financing to support such initiatives.

Major players in the drug repurposing market are F. Hoffmann-La Roche Ltd, International Business Machines Corporation (IBM), Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co. Ltd., Celltrion Inc., Alnylam Pharmaceuticals Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Cosmos Health Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., and BioXcel Therapeutics Inc.

North America was the largest region in the drug repurposing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in drug repurposing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the drug repurposing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug repurposing market consists of revenues earned by entities by providing services such as computational drug screening, clinical trial design and support, regulatory consulting, bioinformatics analysis, and data mining of existing drug databases. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug repurposing market also includes sales of thalidomide, sildenafil, minoxidil, metformin, and azithromycin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The drug repurposing market research report is one of a series of new reports that provides drug repurposing market statistics, including drug repurposing industry global market size, regional shares, competitors with a drug repurposing market share, drug repurposing market segments, market trends and opportunities, and any further data you may need to thrive in the drug repurposing industry. This drug repurposing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug repurposing involves discovering new therapeutic applications for existing or previously unsuccessful drugs. This approach takes advantage of established safety data and pharmacological knowledge to shorten development timelines and reduce costs. The goal is to bring treatments to market more efficiently by skipping the initial stages of drug discovery.

The main approaches to drug repurposing include disease-centric, target-centric, and drug-centric strategies. Disease-centric repurposing involves focusing on a particular disease and evaluating a range of existing drugs to determine their potential efficacy, regardless of their original intended target. The drug types commonly involved are biologics and small molecules. Therapeutic areas include oncology, neurology, infectious diseases, cardiovascular conditions, and autoimmune disorders, with administration routes such as oral, intravenous, topical, inhalation, and intramuscular. These efforts serve various end users, including pharmaceutical companies, academic and research institutions, and contract research organizations.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.